Browse the evidence

Tirzepatide-supported digital weight loss programs achieve high mean weight loss (13.8% over 16 weeks) and high engagement rates, but proactive coaching messaging does not significantly improve weight loss outcomes compared to reactive or control models.

Tirzepatide delivers substantial weight loss (approx 14% in 16 weeks) even with minimal coaching interaction. You do not need to send frequent messages to your coach to lose weight; the medication is the primary driver. Focus on adherence to the dosing schedule and monitoring for side effects rather than trying to maximize engagement metrics.

Bodybuilders who consume dietary supplements (DS) frequently experience adverse side effects, specifically skin rashes (21%), increased liver enzymes (10.8%), and hair loss (9.4%).

If you are taking dietary supplements, monitor your body for changes. The most common issues reported by bodybuilders are skin rashes, hair loss, and elevated liver enzymes. If you notice these symptoms, consult a healthcare provider and review your supplement stack, as they may be contaminated or causing physiological stress.

In middle-aged and older adults, weight gain is associated with an increased risk of atherosclerosis (measured by cIMT > 1.0 mm), particularly in those under 65, those with prior cardiovascular events, and those who are overweight or obese at baseline.

For adults over 45, gaining weight is a clear risk factor for developing atherosclerosis, especially if you are already overweight, obese, or have had heart issues. Focus on maintaining a stable, healthy weight rather than chasing rapid weight loss, which may not improve arterial health markers in this age group.

Digital dietary interventions specifically lead to greater reductions in body weight, BMI, and fasting blood glucose compared to nondigital dietary interventions.

If you are focusing on diet, using a digital tool (app, wearable) may yield better results for weight loss and blood sugar control than traditional methods like pamphlets or face-to-face counseling alone.

Digital physical activity interventions specifically lead to greater reductions in total cholesterol compared to nondigital physical activity interventions.

If you are focusing on exercise, using a digital tool (app, wearable) may yield better results for cholesterol control than traditional exercise programs alone.

Combined digital interventions (dietary, physical activity, and smoking cessation) significantly decrease BMI compared to nondigital combined interventions.

If you are making multiple lifestyle changes (diet, exercise, quitting smoking), using a digital tool may yield better results for BMI reduction than traditional methods alone.

In healthy adults, belonging to the second quartile of dietary glycemic index (GI) is associated with significantly lower odds of having elevated fasting blood glucose (hyperglycemia) compared to the lowest quartile.

You don't need to aim for the absolute lowest glycemic index foods to maintain healthy blood sugar. A moderate GI (second quartile) was associated with lower odds of high fasting blood glucose in this study. Focus on a balanced diet rather than extreme low-GI restrictions.

Replacing servings of low-quality carbohydrates or animal protein with high-quality carbohydrates or plant protein reduces phenotypic age acceleration (PhenoAgeAccel).

To slow biological aging, focus on swapping food sources rather than just cutting calories. Replace one serving of refined grains, sugary drinks, or animal meat with one serving of whole grains, vegetables, nuts, soy, or plant proteins. This substitution is associated with a significant reduction in biological age markers.

High-quality carbohydrate intake is associated with reduced phenotypic age acceleration, but the relationship is non-linear, with potential adverse effects at excessive intake levels.

While high-quality carbohydrates (whole grains, vegetables) generally slow aging, the benefit is not linear. Very high intake may not provide additional benefits and could be detrimental. Aim for a balanced intake of these foods as part of a substitution strategy rather than maximizing them.

BMI mediates the association between macronutrient quality and phenotypic age acceleration, accounting for approximately 20-30% of the effect.

Dietary changes slow aging partly by helping you maintain a healthy weight. If you are trying to slow biological aging, combining high-quality food choices with weight management strategies will be more effective than diet alone.

Shortened sleep duration (40% reduction for 4 nights) impairs adrenergic stimulation of lipolysis in postmenopausal women, reducing lipid efflux and potentially promoting abdominal adiposity independent of caloric intake.

If you are a postmenopausal woman struggling with abdominal fat despite diet and exercise, check your sleep. This research shows that even short-term sleep restriction (reducing sleep by 40% for just 4 nights) blunts your body's ability to break down fat (lipolysis). Prioritizing adequate sleep duration is a critical, often overlooked lever for managing abdominal adiposity in this demographic.

Myostatin and activin A inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) combined with GLP-1 agonists can increase lean mass and reduce fat mass more effectively than GLP-1 agonists alone.

New drugs targeting myostatin (like bimagrumab) are being tested alongside GLP-1s to build muscle while losing fat. These are currently in clinical trials and not yet widely available.

Semaglutide and tirzepatide reduce 'food noise' (constant, pervasive thoughts about food), thereby lowering the mental burden and executive load required to maintain dietary behavior change.

If you feel constantly distracted by thoughts of food ('food noise') despite trying to diet, this is a recognized barrier, not just a lack of willpower. Medications like semaglutide and tirzepatide may reduce this mental burden, making it easier to make deliberate food choices without constant compulsive thinking. This mental relief is often reported as improving quality of life independently of the scale weight.

Semaglutide and tirzepatide increase self-trust and executive functioning regarding food choices by reducing physiological hunger and emotional compulsion, allowing for more deliberate dietary decisions.

If you know what to eat but struggle to follow through due to hunger, cravings, or emotional eating, these medications may help by reducing the physiological drive and emotional compulsion. This can restore your ability to trust yourself and make deliberate, planned food choices rather than reactive ones.

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.

Tirzepatide (2.5 mg weekly) significantly improves glycemic control and reduces body weight in patients with type 2 diabetes during Ramadan fasting, with a favorable safety profile characterized by mild gastrointestinal side effects and no reported hypoglycemia.

If you have type 2 diabetes and plan to fast during Ramadan, tirzepatide (2.5 mg weekly) can help improve your blood sugar and weight without causing low blood sugar. You might experience mild stomach issues like nausea, but these are usually manageable and do not require stopping the medication or breaking your fast. Consult your doctor to ensure it fits your overall treatment plan.

In patients with diabetes, the combination of a healthy diet style and sleep disorders significantly moderates the relationship with waist circumference, indicating that sleep disturbances can negate or alter the protective effects of healthy dietary patterns on abdominal obesity.

For diabetic patients, managing waist circumference requires attention to both diet and sleep. Even with a healthy diet, sleep disorders can negatively impact abdominal obesity. Prioritize sleep hygiene alongside dietary changes to maximize metabolic benefits.

Consumption of sugar-sweetened beverages (SSBs) is positively associated with increased waist circumference and BMI in diabetic patients, independent of other dietary factors.

Reduce or eliminate sugar-sweetened beverages to help manage waist circumference and BMI. This is a key dietary modification for diabetic patients.

Personalized prevention strategies using biomarkers (genetics, omics, imaging) are necessary to predict individual response to lifestyle interventions and optimize cardiovascular risk reduction.

Current risk assessments may not be precise enough for everyone. Future care may involve genetic or biomarker testing to predict exactly which lifestyle changes (diet, exercise type/intensity) will work best for you, moving away from a one-size-fits-all approach.

Higher relative intake of dietary protein is inversely associated with the risk of coronary artery disease (CAD), based on observational data.

If you are concerned about coronary artery disease, this study suggests that ensuring adequate protein intake may be beneficial. Higher relative protein intake was linked to a lower risk of CAD. Include protein-rich foods in your diet. Consult your doctor for personalized advice, especially if you have existing kidney conditions.

A natural spoken language application (COCO) provides valid estimates of total energy intake (TEI) comparable to the gold-standard 24-hour dietary recall method.

To accurately track your calorie intake without the hassle of manual entry, try using a voice-activated nutrition app. This study shows that speaking your meals into an app provides energy estimates just as accurate as professional dietary recalls, making it a viable tool for weight management if you struggle with traditional logging methods.

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

Mediterranean and low-carbohydrate diets combined with exercise reduce cardiovascular and metabolic risk factors in prostate cancer patients undergoing androgen deprivation therapy (ADT).

If you are undergoing hormone therapy for prostate cancer, adopting a Mediterranean or low-carbohydrate diet alongside regular exercise can help manage metabolic risks like weight gain and blood sugar issues. While the benefits are clear, sticking to these changes long-term can be challenging, so focus on consistency over perfection.

Multidisciplinary care and community involvement improve accountability and outcome durability for prostate cancer patients undergoing ADT.

To maintain the benefits of diet and exercise during ADT, consider engaging with multidisciplinary care teams or community support groups. These resources can help you stay accountable and sustain your progress over time.